Efforts in biomarker development andtesting for additional markers such as HER2 in DCIS for risk stratification,49, 50, 51 combined with evidence for the use of moretolerable endocrine therapies for both invasive breast cancer and DCIS 52,53 should refineour treatment approaches. Here, ERBB2 is linked to ductal breast carcinoma in situ.